MarketsandMarkets is delighted to announce the Biomarker and Companion Diagnostics Conference, scheduled to be held on the 5th and 6th of October 2023 in the vibrant city of Frankfurt, Germany. This highly anticipated conference will bring together leading experts, researchers, clinicians, and industry professionals from around the world to delve into the latest advancements and trends in the field of biomarkers and companion diagnostics.

Conference Registration: https://events.marketsandmarkets.com/biomarker-and-companion-diagnostics-conference-germany/register

The Biomarker and Companion Diagnostics Conference will serve as a unique platform for attendees to engage in thought-provoking discussions, gain insights into innovative technologies, and explore the evolving landscape of biomarker discovery and companion diagnostics. The event will feature keynote presentations, interactive panel discussions, and specialized workshops that will cover a wide range of topics, including precision medicine, liquid biopsies, molecular diagnostics, regulatory considerations, and personalized healthcare. With ample networking opportunities, participants will have the chance to connect with like-minded professionals, fostering collaborations that can drive the development and implementation of biomarkers and companion diagnostics. Join us in Frankfurt for this transformative conference and be at the forefront of revolutionizing patient care through biomarker-driven strategies.

MarketsandMarkets Conferences

MarketsandMarkets Conferences

Based on real examples, reflect on the challenges encountered and solutions developed to detect NAb for immunogenicity assessment with Dr.Regina Bruyns and Sripriya Jaganathan on April 20 at 4pm CET.

In this 45-minute interactive event, we will address the following points:
• Neutralizing anti-drug antibodies
• Competitive ligand binding assay formats to detect NAb
• Challenges in NAb detection
• Approaches to minimize drug interference in NAb assays
• Live Q & A session

Join us, it's 100% FREE.

REGISTER HERE: https://zoom.us/webinar/register/2916177964737/WN__ae_VvMPT0yxvuMtOZNhvQ

Researchers have discovered that an aggressive form of pancreatic cancer 'hijacks' the immune system's response and therefore is more likely to respond to treatment with immunotherapy, raising hopes for new targets in the fight against the disease.

Scientists at The Institute of Cancer Research (ICR), London, and The Royal Marsden NHS Foundation Trust, working with colleagues at the University and Hospital Trust of Verona, Italy, used artificial intelligence (AI) and genetic analysis to study 207 tumour samples from patients with pancreatic neuroendocrine tumours for the levels of 600 immune-related genes.

Comparing four separate forms of the disease, they found that samples of the most aggressive form, known as metastases-like primary tumours, saw changes in activity of 74 immune-related genes, compared with changes in only 12 in the more benign insulinoma-like tumours.

http://www.pharmatimes.com/news/immunotherapies_could_target_aggressive_pancreatic_cancer,_research_indicates_1347800

Immunotherapies could target aggressive pancreatic cancer, research indicates - PharmaTimes

Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response - News - PharmaTimes

This is going to be just the information anybody around the world needs to know.

We need long life expectancy irrespective of what's happening around us.

Good job

Amgen Oncology is leading the development of novel therapies that specifically harness the body’s T cells, pioneering the first immuno-oncology program using a BiTE®, or bispecific T cell engager. Explore the world of BiTE® immunotherapy as Amgen scientists Dr. Dirk Nagorsen and Dr. Peter Kufer discuss the current cancer treatment landscape, explain how BiTE® works and offer a preview of how Amgen is bringing this technology into the future of cancer treatment.

Ulcerative colitis is a common form of inflammatory bowel disease. For many people with the condition, widely prescribed anti-inflammatory or immunosuppressive drugs do not remain effective for long, and up to 15% of patients will need surgery to remove all or part of the colon within 20 years of diagnosis. This animation explores how insights into the immunobiology of ulcerative colitis are helping researchers to develop innovative treatments.

Read some in-depth articles on ulcerative colitis at https://www.nature.com/collections/qwtdpjcrpg

Our immune systems are at war with cancer. This animation by nature video reveals how monoclonal antibodies can act as valuable reinforcements to shore up our defences – and help battle cancer.
You can find more on this topic at:
http://www.nature.com/milestones/mileantibodies/index.html

This 1.5-day seminar will cover the fundamentals of human immunology for an audience of scientists across different backgrounds working in pharmaceutical and biotech organizations in programs related to immuno-therapy. The course will cover a historical perspective, basic mechanisms, fundamental concepts and practical approaches to developing therapeutics and their combinations to modulate the immune system. Additionally, the class will offer perspectives on how immune responses can be monitored by assessment of biomarkers and modulated through biopharmaceutical intervention. Through group activities, attendees will actively review immunological concepts as well as design functional immunological assays and read-outs.

http://www.pegsummit.com/PEGS_Training_Seminar_Immunology/